1. Home
  2. CLDI vs PFSA Comparison

CLDI vs PFSA Comparison

Compare CLDI & PFSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Calidi Biotherapeutics Inc.

CLDI

Calidi Biotherapeutics Inc.

HOLD

Current Price

$0.95

Market Cap

8.0M

Sector

Health Care

ML Signal

HOLD

PFSA

Profusa Inc.

N/A

Current Price

$0.08

Market Cap

8.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CLDI
PFSA
Founded
2014
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.0M
8.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CLDI
PFSA
Price
$0.95
$0.08
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
80.3K
15.4M
Earning Date
11-13-2025
02-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
122.22
52 Week Low
$0.96
$0.07
52 Week High
$19.20
$12.76

Technical Indicators

Market Signals
Indicator
CLDI
PFSA
Relative Strength Index (RSI) 30.37 40.04
Support Level $0.97 $0.08
Resistance Level $1.12 $0.10
Average True Range (ATR) 0.07 0.02
MACD 0.00 0.00
Stochastic Oscillator 17.11 5.85

Price Performance

Historical Comparison
CLDI
PFSA

About CLDI Calidi Biotherapeutics Inc.

Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.

About PFSA Profusa Inc.

Profusa Inc is a clinical-stage digital health and medical technology company focused on developing biosensing solutions to improve health outcomes for patients with a variety of different diseases and conditions. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.

Share on Social Networks: